Resultado de búsqueda
Hace 20 horas · Liselotte Spettmann (1936–2024) — Begegnungen (1994) for organCarson Cooman, organPublished by Verlag Daniel Kunert in “Präludien und Fantasien (Orgelwerke, ...
- 2 min
- 8
- Carson Cooman
Hace 3 días · We eagerly anticipate Liselotte's contributions to our continued success.” “Liselotte's extensive background in fostering patient-centric innovations, strategic planning, and the integration of technology and therapeutics will be invaluable assets as we navigate TriSalus’ growth trajectory,” Mary Szela, President and CEO of TriSalus.
Hace 3 días · – Accomplished industry veteran brings deep strategic and operational expertise. DENVER--(BUSINESS WIRE)--May 7, 2024-- TriSalus Life Sciences ® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the appointment of Liselotte Hyveled to its Board of Directors.
Hace 3 días · 9,6200 USD. SMARTBROKER+ entdecken. 07.05.2024 - TriSalus Life Sciences Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment ...
Hace 3 días · May 07, 2024 at 07:00 am EDT. TriSalus Life Sciences Inc. announced the appointment of Liselotte Hyveled to its board of directors. Ms. Hyveled brings over two decades of experience stimulating scientific innovation and advancing pharmaceutical pipelines through research and development excellence. Ms.
Hace 3 días · – Accomplished industry veteran brings deep strategic and operational expertise. TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the appointment of Liselotte Hyveled to its Board of Directors.
Hace 3 días · – Accomplished industry veteran brings deep strategic and operational expertise. TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the appointment of Liselotte Hyveled to its Board of Directors.
